To assess the importance of the route of glucose delivery in determining net hepatic glucose balance (NHGB) eight conscious overnight-fasted dogs were given glucose via the portal or a peripheral vein. NHGB was measured using the arteriovenous difference technique during a control and two 90-min glucose infusion periods. The sequence of infusions was randomized. Insulin and glucagon were held at constant basal levels using somatostatin and intraportal insulin and glucagon infusions during the control, portal, and peripheral glucose infusion periods (7±1, 7±1, 7±1 IU/ml; 100±3, 101±6, 101±3 pg/ml, respectively).
Introduction
The effects of insulin and the blood glucose concentration on net hepatic or splanchnic glucose balance have been extensively explored in both man and the dog, but neither can completely explain the magnitude of hepatic glucose uptake observed after an oral glucose meal. DeFronzo et al. (1) found that in man with basal arterial glucose levels (94±2 mg/dl) and very high insulin concentrations (1,189±414 ,gU/ml), net splanchnic glucose uptake reached 0.68±0.13 mg/kg per min, but still accounted for only 6% of total glucose utilization. Studies from our lab have shown that in dogs in the presence of euglycemia, constant basal glucagon levels, and portal vein hyperinsulinemia as high as 500 ,U/ml, net hepatic glucose uptake did not exceed 0.56±0.27 mg/kg per min (Frizzell, R. T., G. K In man, marked hyperglycemia (224±2 mg/dl) in the presence of basal insulin and glucagon levels produced net splanchnic glucose uptake of only 0.58 mg/kg per min (2) . In the dog under similar conditions net hepatic glucose production was 0.90±0.10 mg/kg per min and there was no net hepatic glucose uptake (3) .
It is clear, therefore, that within the physiologic range neither hyperinsulinemia nor hyperglycemia alone can cause significant net hepatic or splanchnic glucose uptake.
The data are more variable in studies in which hyperinsulinemia and hyperglycemia of the magnitude noted above were combined. In man Sacca et al. (4) and DeFronzo et al. (5) observed net splanchnic glucose uptake of 1.7 and 1.1 mg/kg per min, respectively, in response to combined hyperglycemia and hyperinsulinemia. In dogs made hyperglycemic and hyperinsulinemic net hepatic glucose uptake ranged from 0.9 to 3.8 mg/kg-min (6) (7) (8) . Despite the range of response it is apparent that even combined hyperglycemia and hyperinsulinemia cannot account for the rate of net hepatic and splanchnic glucose uptake seen following oral glucose administration. DeFronzo et al. (5) reported a net splanchnic uptake of 5.9±0.6 mg/kg per min after oral glucose administration in man. Net hepatic glucose uptake ranged from 2.3±0.4 to 5.4±0.5 mg/kg per min (6, (8) (9) (10) in dogs given glucose orally. In those studies insulin levels 1 h after the glucose meal ranged from 41 to 153 uU/ml and glucose levels ranged from 173 to 224 mg/dl clearly not greater than those achieved in the aforementioned studies in which intravenous hyperglycemia and hyperinsulinemia were combined. Such findings led DeFronzo et al. ( 11) to propose the existence of a "gut factor," the presence of which could augment net hepatic glucose uptake.
Since the proposition of this gut factor, other studies have cast doubt on its importance by producing hyperglycemia via an intraportal glucose infusion (6, 8, 10) and triggering rates of hepatic glucose uptake similar to those seen after oral glucose feeding. When hyperinsulinemia and hyperglycemia of portal intravenous origin were combined net hepatic glucose uptakes were as large as those observed after oral glucose administration (2.5±0.8 vs. 2.3±0.4 (10), 6.0±1.4 vs. 5.4±0.5 (8) 16 d before each experiment, a laparotomy was performed under general anesthesia (sodium pentobarbitol, 25 mg/kg), and Silastic catheters were inserted into a splenic vein, the portal vein, the left common hepatic vein, and a jejunal vein. The tips of the splenic and jejunal catheters were such that they were 1 cm beyond the first site of coalescence of the catheterized vein with another vessel. The tip ofthe portain vein catheter was placed 2 cm from the point at which the vessel enters the liver, and the tip ofthe hepatic vein catheter was placed 1 cm inside the left common hepatic vein. In the dog the left common hepatic vein drains the blood from almost half of the liver, the largest portion of liver drained by any of the hepatic veins (12) . Another catheter was placed in the left femoral artery following a cut-down in the left inguinal region. After the catheters were inserted, they were filled with saline containing heparin (200 U/ ml, Abbott Laboratories, North Chicago, IL), their free ends were knotted, and they were placed in subcutaneous pockets so that complete closure of the incisions was possible. Two weeks after surgery, blood was drawn to determine the leukocyte count and the hematocrit ofthe animal. Only animals that had (a) a leukocyte count below 16,000/mm3, (b) a hematocrit above 38%, (c) a good appetite (consuming all of the daily ration), and (d) normal stools were used.
On the day of an experiment, the subcutaneous ends of the catheters were freed through a small skin incision made under local anesthesia (2% Lidocaine, Astra Pharmaceutical Products, Worcester, MA). The contents of each catheter were aspirated and the catheters were flushed with saline. The catheters in the splenic and jejunal veins were used for intraportal infusion of insulin, glucagon, and glucose, while the portal vein, hepatic vein, and femoral artery catheters were used for blood sampling. Three Angiocaths (18- ( 16) . Whole blood lactate concentrations were determined using a Technicon Auto-Analyzer according to the method of Lloyd et al. (15) . The immunoreactive glucagon concentration in plasma samples to which 500 U/ml Trasylol had been added was determined using the 30 K antiserum of Unger (17) . Immunoreactive insulin was measured using the Sephadex bound antibody procedure (18) . Indocyanine green (Hynson, Westcott, and Dunning, Inc., Baltimore, MD) was measured spectrophotometrically at 810 nm to estimate hepatic blood flow according to the method of Leevy (19) .
Calculations and data analysis. Net hepatic glucose balance (NHGB)' was determined using three separate methods. In the first, referred to as the "direct" calculation, NHGB was determined by the formula [0.28A + 0.72P -H] X HBF, where A is the arterial glucose concentration, P the portal vein glucose concentration, H the hepatic vein glucose concentration, and HBF the hepatic blood flow. The proportion of hepatic blood supply provided by the hepatic artery was assumed to be 28% based on a compilation of data from many sources by Greenway and Stark (20) . It is unlikely that somatostatin at the dose employed, would have significantly altered this ratio since in all of our published studies (21, 22) hepatic blood flow in the dog was unchanged when somatostatin and basal replacement amounts ofinsulin and glucagon were given. Furthermore in the present study the mean blood flow was not significantly different from those observed in overnight fasted dogs given saline only. It is unlikely that the peripheral or portal infusion ofglucose would have altered this ratio since total blood flow did not change in our study and neither total flow nor the distribution of flow in the two vessels was altered by similar infusions in earlier dog studies by Ishida et al. (8) in which Doppler flow probes were used to measure flow in the portal vein and hepatic artery directly.
To calculate NHGB during the portal glucose infusion without relying on the portal vein glucose concentration or on the assumption that 72% of hepatic blood flow is derived from the portal vein, the following formula, referred to as the "indirect" method was used: NHGB = NSGB + NGGB -GI; NSGB being net splanchnic glucose balance (calculated by multiplying the splanchnic A -V difference for glucose by hepatic blood flow), GI being the amount of glucose infused into the portal system and NGGB being net gut glucose balance (calculated by multiplying the gut A -V difference for glucose by 0.72 HBF). During the portal glucose infusion period the portal vein glucose concentration cannot be used to calculate NGGB since the portal blood sample is taken downstream from the site of entry of the glucose infusion. Therefore, NGGB during portal glucose delivery was assumed to be the same as NGGB during peripheral glucose delivery, since the glucose concentration in arterial blood was similar during the two infusion periods.
NHGB was also estimated using tritiated glucose data in a method referred to as the "tracer-derived NHGB." This was done by dividing the net hepatic uptake of A) X HBF. Glucose uptake by the peripheral tissues (PGU), including all tissues other than the liver, was calculated using the formula PGU = HI -NHGB. Fractional extraction of glucose by the liver was calculated using the formula NHGB/HGL. NHGB used in the above calculations was that determined using the direct method.
The total rate of glucose production (Ra) was determined by means of a primed tracer infusion. Calculation of the rate was carried out according to the method of Wall et al. (23) as simplified by Debodo et al. (24) . This method is based on a single-compartment analysis of glucose kinetics in which it is assumed that rapid changes in the specific activity and concentration of glucose do not occur uniformly within the entire glucose pool. To compensate for this nonuniform mixing, the nonsteady state term of the equation was multiplied by a correction factor (pool fraction) of 0.65 as suggested by Cowan and Hetenyi (25) . Total hepatic glucose uptake (THGU) can be calculated by subtracting NHGB from Ra. The direct NHGB was used to calculate THGU.
Net splanchnic, hepatic, and gut lactate balances were calculated using hepatic blood flow and blood lactate values and the formulae given for determination of glucose balance.
It should be noted that steady state conditions existed for the control period and the latter part of each test period thus the mean±SEM data shown in Figs. 2-6 represent the data from the control period and the last 30 min of each test period for both protocols. Statistical significance was determined using the paired t test (26) .
Results
Insulin and glucagon levels. The arterial plasma insulin and glucagon levels remained unchanged throughout each study regardless of the protocol employed ( Fig. I and Fig. 2 (Fig. 3) . Hepatic blood flow was similar during the two glucose infusion periods (Fig.  3) , consequently, the hepatic glucose load was not significantly (P > 0.05) different in the two periods (Fig. 3 , Table I ).
NHGB and thefractional extraction ofglucose by the liver.
The net hepatic glucose balance (n = 8) was 2.22±0.28 and 0.08±0.23 mg/kg per min during the control period and the peripheral glucose infusion period, respectively (Fig. 4) . During the portal glucose infusion period, the liver switched to net hepatic glucose uptake of - Values given for individual dogs represent the mean value over the entire control period and over the last 30 min of the glucose infusion periods.
3H-balance by the liver during the control period was -0.74±0.26 mg/kg per min. * Not measured. P < 0.05) during portal glucose infusion than during peripheral glucose infusion (Table I ). The arterial-portal glucose gradient was 2±1, 4±1, and -22±3 mg/dl during the control period, peripheral infusion period, and portal infusion period, respectively (Fig. 4) . There was a significant correlation between the arterial-portal glucose gradient and net hepatic glucose balance (r = 0.82, P < 0.05) (Fig. 5) .
Glucose turnover. The tracer-determined R. was 3.50±0.74 mg/kg per min (Table III) (Fig. 6) .
Lactate metabolism. The liver produced lactate throughout the control period of each protocol and significantly increased its lactate production in response to glucose loading (Table IV) . There was no significant difference in lactate production during the two glucose infusion periods.
Discussion
This study demonstrates that hyperglycemia induced by intraportal glucose delivery can bring about significant net hepatic ) . Furthermore, the measured arterial-portal glucose gradient is a good predictor of mixing. In other words, when the measured arterial-portal glucose difference is equal to the difference predicted by dividing the glucose infusion rate by portal blood flow, the infused glucose can be considered to have mixed well. In the present study, three measurements ofthe arterial-portal glucose gradient were made during intraportal glucose infusion in each of eight dogs, giving a total of 24 such measurements. In 13 of these, the measured arterial-portal glucose difference was within ± 10% of the predicted difference. In five the measured difference was moderately higher than predicted, and in six, moderately lower than predicted. The error caused by streaming, when it occurred, thus was random and disappeared when means ofthe data were established, (the measured plasma arterial-portal glucose difference was 22±3 mg/dl, whereas the predicted was 26±5 mg/dl). Furthermore, if only the data from the 13 points in which the measured arterial-portal glucose difference equaled the predicted difference were used in calculating the data NHGB was -1.51 mg/kg per min again indicating significant glucose uptake by the liver. Lastly, the NHGB calculated using the tritiated glucose data should not be subject to the streaming problem as the labeled glucose was infused peripherally and was well mixed before reaching the portal system and it too indicated significant hepatic glucose uptake during intraportal glucose infusion.
The individual variation in NHGB from dog to dog and the variation in a given dog when the rate was estimated using the three different approaches (Table II) (Table  II) involves four separate measurements, each of which carries with it some degree of error, and the second and third equations require five and six measured parameters, respectively. In ad- The second technical issue of interest relates to the ratio of blood flow reaching the liver via the portal vein versus the hepatic artery. In the present study the hepatic artery was assumed to supply 28% ofthe blood flow to the liver based on data compiled by Greenway and Stark (20) . This is slightly different from the 20% measured by Ishida et al. (8) Table III . The rate of glucose appearance (Ra) and the total hepatic glucose uptake (THGU = Ra -NHGB) are presented with the following caveats: first, data from protocol II are not presented because in that protocol glucose was given via the portal route first. During portal delivery, net hepatic glucose uptake was significant, suggesting that glycogen synthesis was occurring and that [3H]glucose was being incorporated into glycogen. Thus the glucose being produced via glycogenolysis during the subsequent period (i.e., the peripheral glucose delivery period) contained labeled glucose, falsely lowering the tracer-determined rate ofglucose appearance. The second caveat relates to problems encountered using the pool fraction model to analyze glucose kinetics in the presence ofan infusion ofa relatively large amount of cold glucose. There is an acknowledged but undefined error in the method (27) that is apparent from the frequent finding of negative rates of endogenous glucose appearance (Ra-glucose infusion rate) thus indicating an underestimate of Ra. In the data given here, negative values for the rate ofglucose appearance were changed to a value of zero thereby minimizing but not eliminating this error. It should also be noted that the error would have been similar in the two glucose infusion periods because the rates of glucose infusion were virtually identical.
In spite of these problems, the tracer data do offer some insight into the effect ofthe route ofglucose delivery on NHGB. Both peripheral and portal glucose delivery caused a suppression of the rate of hepatic glucose production to less than half of the control rate, but peripheral glucose delivery did not increase THGU. Thus, the suppression of NHGB by peripheral glucose delivery was due solely to a decrease in rate ofglucose production.
Portal glucose infusion, however, caused a greater than twofold increase in THGU in addition to the suppression of glucose production.
The liver produced lactate throughout the control period, a finding consistent with data from other postabsorptive dogs (28) , and the production of lactate by the liver was greater during glucose delivery. However, ifanything, it was slightly less during portal glucose infusion than during peripheral glucose infusion, suggesting that the glucose being taken up was not being lost as lactate, but was probably being stored as glycogen. The finding of a smaller uptake of glucose by peripheral tissues during portal glucose delivery as compared with peripheral delivery suggests that the "portal factor" that enhances hepatic glucose uptake also induces some peripheral insulin resistance. The nature of this effect is not clear from the present study although it suggests that either a neural or hormonal factor in involved in that coordination of the response occurs.
The mechanism by which the route of glucose delivery triggers net hepatic glucose uptake is also not known. Neither the load of glucose nor the load of insulin reaching the liver could be factors, as these two parameters were the same during the two infusion periods. Likewise, the small (4%) increase in the portal plasma glucose level is insufficient to explain the switch from a slightly positive net hepatic glucose balance to significant uptake since increasing the glucose level in the portal vein further by peripheral infusion did not trigger net hepatic glucose uptake (29) .
A gut factor is not involved as the gut was bypassed by the intraportal glucose infusion, however a portal factor cannot be discounted. The change in the arterial-portal glucose gradient correlates with the change in net hepatic glucose balance (Fig.  5) , suggesting that a gradient may generate a signal that increases net hepatic glucose uptake. The glucose gradient has previously been related to the control ofanorexia and food intake by Russek (30) , and has recently been reported as a signal for insulin-dependent net hepatic glucose uptake in rat liver perfused simultaneously via the hepatic artery and the portal vein (31). In view of the simultaneous effect on glucose uptake by the liver and the extrahepatic tissues, and because of the speed with which the effect is manifest, a centrally mediated neural mechanism represents an attractive explanation for the phenomenon. Although the perfused liver data mentioned above would seem to contradict this hypothesis, some evidence supports the neural mechanism. Niijima (32) found afferent fibers in the hepatic branch ofthe vagus nerve ofguinea pigs that showed a discharge rate inversely related to the concentration ofglucose in the portal vein. Schmitt (33) reported finding lateral hypothalamic neurons that changed their rate of firing upon injection of glucose into the portal vein. This response was obliterated by cutting the splanchnic nerves, but not by severing the vagi. Shimazu (34, 35) found that electrical stimulation ofthe vagus nerve activated glycogen synthase in both intact and pancreatectomized rabbits, and Shimazu and Fujimoto (36) reported an increased rate of incorporation of ['4C]glucose into liver glycogen with electrical stimulation ofthe vagus in intact and pancreatectomized rabbits. Most interestingly, Lautt (37) proposed that the gut factor previously discussed is actually an autonomic reflex arc. Although current evidence disputes the existence of a gut factor, a portal factor may very well exist, at least in the dog. Furthermore, it may be an autonomic reflex that senses the presence of an arterial-portal glucose gradient and acts on the liver to cause net glucose uptake. Recent work by Chap et al. (38, 39) offers some support to this hypothesis, suggesting that atropine and adrenergic blockers may alter net hepatic glucose uptake after oral glucose in dogs. Other possible mechanisms include a humoral factor or some form of local autoregulation. For example, Drapanas (40) reported a marked increase in portal vein serotonin levels after delivery of hypertonic glucose into the duodenum or jejunum. Gastric inhibitory peptide does not seem to affect the hepatic response to peripherally infused glucose (38).
In summary, this study shows that in overnight-fasted, conscious dogs the intraportal route ofglucose delivery brings about net hepatic glucose uptake even in the presence of basal insulin levels. The distribution of the intraportally infused glucose to the liver and peripheral tissues is similar to that seen after an oral glucose load, and is significantly different from that seen with peripheral glucose delivery. The arterial-portal glucose gradient may be the signal that triggers net hepatic glucose uptake during intraportal glucose delivery. This study indicates that a gut factor is not involved in triggering net hepatic glucose uptake after intraportal or oral glucose delivery, but that a portal factor is necessary for normal glucose distribution. Such a factor would be advantageous to the animal in that it would provide a means of differentiating hyperglycemia of exogenous origin, i.e., a meal, from hyperglycemia of endogenous origin, for example, a response to stress.
